Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib

Bibliographic Details
Main Authors:	Nishan Tchekmedyian, MD, Bill Paxton, MD, PhD, Francois Lebel, MD, Lena Keossayan, BA, John V. Heymach, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2020-11-01
Series:	JTO Clinical and Research Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364320301041

id	doaj-c8d34ceb341d421196b3ea04c4014128
record_format	Article
spelling	doaj-c8d34ceb341d421196b3ea04c40141282021-03-19T07:29:31ZengElsevierJTO Clinical and Research Reports2666-36432020-11-0114100081Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line PoziotinibNishan Tchekmedyian, MD0Bill Paxton, MD, PhD1Francois Lebel, MD2Lena Keossayan, BA3John V. Heymach, MD, PhD4Pacific Shores Medical Group, Huntington Beach, California; Corresponding author. Address for correspondence: Nishan Tchekmedyian, MD, Pacific Shores Medical Group, 19582 Beach Blvd. #212, Huntington Beach, CA 92648.Spectrum Pharmaceuticals, Irvine, CaliforniaSpectrum Pharmaceuticals, Irvine, CaliforniaPacific Shores Medical Group, Huntington Beach, CaliforniaDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texashttp://www.sciencedirect.com/science/article/pii/S2666364320301041
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Nishan Tchekmedyian, MD Bill Paxton, MD, PhD Francois Lebel, MD Lena Keossayan, BA John V. Heymach, MD, PhD
spellingShingle	Nishan Tchekmedyian, MD Bill Paxton, MD, PhD Francois Lebel, MD Lena Keossayan, BA John V. Heymach, MD, PhD Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib JTO Clinical and Research Reports
author_facet	Nishan Tchekmedyian, MD Bill Paxton, MD, PhD Francois Lebel, MD Lena Keossayan, BA John V. Heymach, MD, PhD
author_sort	Nishan Tchekmedyian, MD
title	Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
title_short	Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
title_full	Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
title_fullStr	Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
title_full_unstemmed	Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib
title_sort	prolonged central nervous system response in a patient with her2 mutant nsclc treated with first-line poziotinib
publisher	Elsevier
series	JTO Clinical and Research Reports
issn	2666-3643
publishDate	2020-11-01
url	http://www.sciencedirect.com/science/article/pii/S2666364320301041
work_keys_str_mv	AT nishantchekmedyianmd prolongedcentralnervoussystemresponseinapatientwithher2mutantnsclctreatedwithfirstlinepoziotinib AT billpaxtonmdphd prolongedcentralnervoussystemresponseinapatientwithher2mutantnsclctreatedwithfirstlinepoziotinib AT francoislebelmd prolongedcentralnervoussystemresponseinapatientwithher2mutantnsclctreatedwithfirstlinepoziotinib AT lenakeossayanba prolongedcentralnervoussystemresponseinapatientwithher2mutantnsclctreatedwithfirstlinepoziotinib AT johnvheymachmdphd prolongedcentralnervoussystemresponseinapatientwithher2mutantnsclctreatedwithfirstlinepoziotinib
_version_	1724213354493378560

Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib

Similar Items